Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Having Cake & Eating It: Sunesis' Solution to the Development/Discovery Challenge

This article was originally published in Start Up

Executive Summary

The funding squeeze has relaxed, but discovery still doesn't attract much investor attention. Discovery-based Sunesis has opted to have its cake and eat it, too. It in-licensed at an early stage and thus didn't threaten its research group. And it's given its researchers perhaps another year and a half before they've got to put an invention of their own into the clinic-or in-license something else.

You may also be interested in...



Securing PIPEs to Progress Fledgling Clinical Portfolios

Many of the small biotech companies that have listed on the public markets in the past few years have had to grapple with less-than-hoped-for IPO proceeds, low market valuations, and poor share liquidity. PIPE financings are allowing some of these companies to progress promising portfolios and offering investors potential upside on undervalued assets.

Securing PIPEs to Progress Fledgling Clinical Portfolios

Many of the small biotech companies that have listed on the public markets in the past few years have had to grapple with less-than-hoped-for IPO proceeds, low market valuations, and poor share liquidity. PIPE financings are allowing some of these companies to progress promising portfolios and offering investors potential upside on undervalued assets.

Biotech Layoffs Hit Hardest In Discovery

As the financing drought continues and their cash supplies dwindle, biotechs are resorting to big layoffs to drastically cut back on spending (See exhibit 1). But however rigorous a company's turnaround effort, the target of the layoffs always seems to be discovery research, with the remaining employees focusing on clinical programs.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090907

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel